Current partner codePEPTIDESDE
NCT00402337·Phase 2·INTERVENTIONAL

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

Status

Completed

Phase

Phase 2

Enrollment

310

Locations

60

Results

Posted

Publications

1

Study summary

What the protocol is testing.

The primary purpose of this study is to evaluate the efficacy and safety of administration of linaclotide acetate in patients with chronic constipation.

Interventions

Treatment arms and agents.

DRUG

linaclotide acetate

oral, once daily.

DRUG

Matching placebo

oral, once daily

Timeline

From registration to results.

  1. First posted

    Nov 22, 2006

  2. Study start

    Nov 2006

  3. Primary completion

    Dec 2007

  4. Study completion

    Feb 2008

  5. Results posted

    Mar 5, 2013

  6. Registry updated

    Mar 5, 2013

Outcomes

What the study measures.

Primary outcomes

Change From Pretreatment in Weekly Normalized Spontaneous Bowel Movement (SBM) Frequency

Time frame · Change from Baseline to Week 4

Change in SBM frequency during Weeks 1 through 4 of the treatment period from the weekly SBM rate obtained during the pretreatment period.

Secondary outcomes

SBM 75% Responder for the Treatment Period (Based on the Normalized Rate)

Time frame · Change from Baseline to Week 4

A patient was an SBM 75% Responder if the patient was an SBM Responder for ≥3 of the 4 treatment period weeks. For each week of the treatment and postreatment periods, a patient was considered an SBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had an SBM rate of ≥ 3 for the week, and 3) had an increase in SBM rate of ≥ 1 from their baseline weekly SBM rate.

CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)

Time frame · Change from Baseline to Week 4

A patient was a complete spontaneous bowel movement (CSBM) 75% Responder if the patient was a CSBM Responder for ≥3 of the 4 treatment period weeks. For each week of the treatment and postreatment periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from their baseline weekly CSBM rate.

Change From Baseline in the Weekly Normalized CSBM Rate for the Treatment Period

Time frame · Change from Baseline to Week 4

CSBMs measured daily during the treatment period. During each daily phone call into the IVRS, patients were asked: How many bowel movements did you have today or yesterday after your last call?

Change From Baseline in Stool Consistency (BSFS) Score for the Treatment Period

Time frame · Change from Baseline to Week 4

Stool consistency analyses were performed using the 7-point BSFS, whereby a score of 1 = difficult to pass; 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = entirely liquid.

Change From Baseline in Straining Score for the Treatment Period

Time frame · Change from Baseline to Week 4

Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Patient is 18 years of age or older * Patient meets colonoscopy requirements according to the American Gastroenterological Association * Patient meets criteria for chronic constipation including weekly bowel movement frequency requirements and reports one or more symptoms of constipation according to protocol requirements * Patient has successfully completed study requirements with no clinically-significant findings: physical exam, ECG, clinical laboratory tests * Patient is fluent in English Exclusion Criteria: * Patient reports loose or watery stools * Patient meets criteria for IBS including protocol-defined abdominal discomfort or pain * Patient may not take prohibited medications per protocol * Medical diagnoses, medical conditions, or family history that would not make the patient a good candidate for the study or limit the patient's ability to complete the clinical study

Study locations

60 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Microbia Investigational Site

Huntsville, Alabama, United States

Microbia Investigational Site

Tucson, Arizona, United States

Microbia Investigational Site

Sherwood, Arkansas, United States

Microbia Investigational Site

Anaheim, California, United States

Microbia Investigational Site

Sacramento, California, United States

Microbia Investigational Site

San Diego, California, United States

Microbia Investigational Site

Boulder, Colorado, United States

Microbia Investigational Site

Bristol, Connecticut, United States

Microbia Investigational Site

Boynton Beach, Florida, United States

Microbia Investigational Site

Port Orange, Florida, United States

Microbia Investigational Site

Tampa, Florida, United States

Microbia Investigational Site

Stockbridge, Georgia, United States

Microbia Investigational Site

Peoria, Illinois, United States

Microbia Investigational Site

Indianapolis, Indiana, United States

Microbia Investigational Site

Clive, Iowa, United States

Microbia Investigational Site

Davenport, Iowa, United States

Microbia Investigational Site

Louisville, Kentucky, United States

Microbia Investigational Site

Monroe, Louisiana, United States

Microbia Investigational Site

Silver Spring, Maryland, United States

Microbia Investigational Site

Boston, Massachusetts, United States

Microbia Investigational Site

Ann Arbor, Michigan, United States

Microbia Investigational Site

Traverse City, Michigan, United States

Microbia Investigational Site

Olive Branch, Mississippi, United States

Microbia Investigational Site

Lincoln, Nebraska, United States

Related trials

More studies on Linaclotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.